These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 15044431)
1. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. Kartsonis NA; Saah A; Lipka CJ; Taylor A; Sable CA J Antimicrob Chemother; 2004 May; 53(5):878-81. PubMed ID: 15044431 [TBL] [Abstract][Full Text] [Related]
2. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Keating G; Figgitt D Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760 [TBL] [Abstract][Full Text] [Related]
3. Comparison of caspofungin and amphotericin B for invasive candidiasis. Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J; N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683 [TBL] [Abstract][Full Text] [Related]
4. Caspofungin: a review of its use in the treatment of fungal infections. McCormack PL; Perry CM Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025 [TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300 [TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208 [TBL] [Abstract][Full Text] [Related]
11. Caspofungin for the treatment of less common forms of invasive candidiasis. Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917 [TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017 [TBL] [Abstract][Full Text] [Related]
13. Caspofungin: a major breakthrough in treatment of systemic fungal infections. Agarwal MB; Rathi SA; Ratho N; Subramanian R J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012 [TBL] [Abstract][Full Text] [Related]
15. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Pelletier R; Alarie I; Lagacé R; Walsh TJ Med Mycol; 2005 Sep; 43(6):559-64. PubMed ID: 16320498 [TBL] [Abstract][Full Text] [Related]
16. Caspofungin acetate for treatment of invasive fungal infections. Pacetti SA; Gelone SP Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942 [TBL] [Abstract][Full Text] [Related]
17. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA; Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331 [TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Arathoon EG; Gotuzzo E; Noriega LM; Berman RS; DiNubile MJ; Sable CA Antimicrob Agents Chemother; 2002 Feb; 46(2):451-7. PubMed ID: 11796357 [TBL] [Abstract][Full Text] [Related]
19. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Maschmeyer G; Glasmacher A Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]